Navitoclax, Navitoclax, RUXOLITINIB
M16-109
Phase 2 small_molecule active
Quick answer
Navitoclax, Navitoclax, RUXOLITINIB for Myelofibrosis is a Phase 2 program (small_molecule) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AbbVie Deutschland GmbH & Co. KG
- Indication
- Myelofibrosis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active